Dr. Purnanand Sarma serves as the President and Chief Executive Officer of Immunome, Inc. (NASDAQ:IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases including COVID-19. Sarma has more than 25 years of experience in the pharmaceutical industry across multiple R&D platforms and led the development of therapeutics in companies ranging from venture-backed biotechnology start-ups to large cap pharmaceutical companies.

He was most recently the President & CEO of Taris Biomedical, based in Lexington, MA, which he built into a leader in therapeutic urology, and was acquired by Johnson & Johnson in December 2019.  Earlier at Taris Biomedical, in addition to raising more than $100M in equity capital, he also sold one of Taris’ products to Allergan (NYSE:AGN) in a deal worth up to $587M. Prior to Taris, Sarma held leadership positions at Cephalon Corporation, Nektar Therapeutics and Glaxo SmithKline.  Dr. Sarma received a PhD in Pharmaceutics from the University of Minnesota, and a B.Pharm degree from Andhra University, Visakhapatnam, India.

Sarma recently joined Immunome as its President, CEO and Board Member.  Under his leadership, the company completed its initial public offering in October 2020. Immunome’s proprietary technology leverages immune response from patients who successfully learned to fight off the disease, specifically by probing their highly-educated memory B-cells, to discover novel therapeutic antibodies, and their targets.  The company is currently focused on developing drugs to treat cancer, and infectious diseases, including COVID-19.  In July 2020, the United States Department of Defense awarded a $13.3 million contract to Immunome for the development of a novel biosynthetic convalescent plasma (BCP) as a potential new approach to combat the COVID-19 pandemic.  

|